The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior

Jing Du, Thomas K. Creson, LongJun Wu, Ming Ren, Neil A. Gray, Cynthia Falke, Yanling Wei, Yun Wang, Rayah Blumenthal, Rodrigo Machado-Vieira, Peixiong Yuan, Guang Chen, Min Zhuo, Husseini K. Manji

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The cellular basis underlying the complex clinical symptomatology of bipolar disorder and the mechanisms underlying the actions of its effective treatments have not yet been fully elucidated. This study investigated the role of hippocampal synaptic AMPA receptors. We found that chronic administration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 in hippocampal neurons in vitro and in vivo. Electrophysiological studies confirmed that the AMPA/NMDA ratio was reduced in CA1 regions of hippocampal slices from lithium-treated animals. Reduction in GluR1 phosphorylation at its cAMP-dependent protein kinase A site by the synthetic peptide TAT-S845, which mimics the effects of lithium or VPA, was sufficient to attenuate surface and synaptic GluR1/2 levels in hippocampal neurons in vitro and in vivo. Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)- benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity. These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders.

Original languageEnglish (US)
Pages (from-to)68-79
Number of pages12
JournalJournal of Neuroscience
Volume28
Issue number1
DOIs
StatePublished - Jan 2 2008
Externally publishedYes

Fingerprint

Lithium
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Neurotransmitter Receptor
AMPA Receptors
Valproic Acid
Cyclic AMP-Dependent Protein Kinases
Antimanic Agents
Hippocampal CA1 Region
Neurons
Peptides
Pleasure
Amphetamine
N-Methylaspartate
Bipolar Disorder
Phosphorylation
Therapeutics
AMPA 2 glutamate receptor ionotropic
In Vitro Techniques
GYKI 52466

Keywords

  • AMPA
  • Lithium
  • Manic-like behavior
  • Phosphorylation
  • PKA
  • Valproate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. / Du, Jing; Creson, Thomas K.; Wu, LongJun; Ren, Ming; Gray, Neil A.; Falke, Cynthia; Wei, Yanling; Wang, Yun; Blumenthal, Rayah; Machado-Vieira, Rodrigo; Yuan, Peixiong; Chen, Guang; Zhuo, Min; Manji, Husseini K.

In: Journal of Neuroscience, Vol. 28, No. 1, 02.01.2008, p. 68-79.

Research output: Contribution to journalArticle

Du, J, Creson, TK, Wu, L, Ren, M, Gray, NA, Falke, C, Wei, Y, Wang, Y, Blumenthal, R, Machado-Vieira, R, Yuan, P, Chen, G, Zhuo, M & Manji, HK 2008, 'The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior', Journal of Neuroscience, vol. 28, no. 1, pp. 68-79. https://doi.org/10.1523/JNEUROSCI.3080-07.2008
Du, Jing ; Creson, Thomas K. ; Wu, LongJun ; Ren, Ming ; Gray, Neil A. ; Falke, Cynthia ; Wei, Yanling ; Wang, Yun ; Blumenthal, Rayah ; Machado-Vieira, Rodrigo ; Yuan, Peixiong ; Chen, Guang ; Zhuo, Min ; Manji, Husseini K. / The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. In: Journal of Neuroscience. 2008 ; Vol. 28, No. 1. pp. 68-79.
@article{4ec96e900fe24c23a86a12d3cfcede92,
title = "The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior",
abstract = "The cellular basis underlying the complex clinical symptomatology of bipolar disorder and the mechanisms underlying the actions of its effective treatments have not yet been fully elucidated. This study investigated the role of hippocampal synaptic AMPA receptors. We found that chronic administration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 in hippocampal neurons in vitro and in vivo. Electrophysiological studies confirmed that the AMPA/NMDA ratio was reduced in CA1 regions of hippocampal slices from lithium-treated animals. Reduction in GluR1 phosphorylation at its cAMP-dependent protein kinase A site by the synthetic peptide TAT-S845, which mimics the effects of lithium or VPA, was sufficient to attenuate surface and synaptic GluR1/2 levels in hippocampal neurons in vitro and in vivo. Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)- benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity. These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders.",
keywords = "AMPA, Lithium, Manic-like behavior, Phosphorylation, PKA, Valproate",
author = "Jing Du and Creson, {Thomas K.} and LongJun Wu and Ming Ren and Gray, {Neil A.} and Cynthia Falke and Yanling Wei and Yun Wang and Rayah Blumenthal and Rodrigo Machado-Vieira and Peixiong Yuan and Guang Chen and Min Zhuo and Manji, {Husseini K.}",
year = "2008",
month = "1",
day = "2",
doi = "10.1523/JNEUROSCI.3080-07.2008",
language = "English (US)",
volume = "28",
pages = "68--79",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "1",

}

TY - JOUR

T1 - The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior

AU - Du, Jing

AU - Creson, Thomas K.

AU - Wu, LongJun

AU - Ren, Ming

AU - Gray, Neil A.

AU - Falke, Cynthia

AU - Wei, Yanling

AU - Wang, Yun

AU - Blumenthal, Rayah

AU - Machado-Vieira, Rodrigo

AU - Yuan, Peixiong

AU - Chen, Guang

AU - Zhuo, Min

AU - Manji, Husseini K.

PY - 2008/1/2

Y1 - 2008/1/2

N2 - The cellular basis underlying the complex clinical symptomatology of bipolar disorder and the mechanisms underlying the actions of its effective treatments have not yet been fully elucidated. This study investigated the role of hippocampal synaptic AMPA receptors. We found that chronic administration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 in hippocampal neurons in vitro and in vivo. Electrophysiological studies confirmed that the AMPA/NMDA ratio was reduced in CA1 regions of hippocampal slices from lithium-treated animals. Reduction in GluR1 phosphorylation at its cAMP-dependent protein kinase A site by the synthetic peptide TAT-S845, which mimics the effects of lithium or VPA, was sufficient to attenuate surface and synaptic GluR1/2 levels in hippocampal neurons in vitro and in vivo. Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)- benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity. These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders.

AB - The cellular basis underlying the complex clinical symptomatology of bipolar disorder and the mechanisms underlying the actions of its effective treatments have not yet been fully elucidated. This study investigated the role of hippocampal synaptic AMPA receptors. We found that chronic administration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 in hippocampal neurons in vitro and in vivo. Electrophysiological studies confirmed that the AMPA/NMDA ratio was reduced in CA1 regions of hippocampal slices from lithium-treated animals. Reduction in GluR1 phosphorylation at its cAMP-dependent protein kinase A site by the synthetic peptide TAT-S845, which mimics the effects of lithium or VPA, was sufficient to attenuate surface and synaptic GluR1/2 levels in hippocampal neurons in vitro and in vivo. Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)- benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity. These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders.

KW - AMPA

KW - Lithium

KW - Manic-like behavior

KW - Phosphorylation

KW - PKA

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=38149100380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149100380&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.3080-07.2008

DO - 10.1523/JNEUROSCI.3080-07.2008

M3 - Article

C2 - 18171924

AN - SCOPUS:38149100380

VL - 28

SP - 68

EP - 79

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 1

ER -